CompanyGraphWhat stands out
- Valued far above the size of its business
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is $2B, above the global median of $1.15B
- FinancialsAltman Z-Score 10.02: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
13.43BCNY2.00B · vs all stocks (USD)
Revenue (TTM)
812.23MCNY120.79M · vs all stocks (USD)
Profit Margin
-2.93%52-Week Change
127.16%vs all stocks
Market Capitalization
13.43BCNY2.00B · vs all stocks (USD)
Enterprise Value
11.67BCNY1.73B · vs all stocks (USD)
Price to Sales (TTM)
17.47xPrice to Book (MRQ)
6.07xEnterprise to Revenue
14.36xGross Margin
30.76%Profit Margin
-2.93%Operating Margin
10.86%Return on Assets (TTM)
-0.64%Return on Equity (TTM)
-0.01%Revenue (TTM)
812.23MCNY120.79M · vs all stocks (USD)
Revenue per Share (TTM)
5.88CNYUpdated Aug 21, 2026Quarterly Revenue Growth
0.40%Gross Profit (TTM)
146.45MCNY21.78M · vs all stocks (USD)
EBITDA (TTM)
125.96MCNY18.73M · vs all stocks (USD)
Net Income (TTM)
-23.83MCNY-3.54M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
121.20%Operating Cash Flow (TTM)
249.50MCNY37.10M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
99.41MCNY14.78M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
38.58MCNYFY2025 · Dec 31, 2025Revenue
811.33MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
600.73MCNYFY2025 · Dec 31, 2025Gross Profit
210.59MCNYFY2025 · Dec 31, 2025Operating Income
22.87MCNY3.40M · vs all stocks (USD)
Pre-tax Income
-16.30MCNYFY2025 · Dec 31, 2025Income Tax Expense
-5.81MCNYFY2025 · Dec 31, 2025Net Income
-10.48MCNYFY2025 · Dec 31, 2025EBIT
-7.76MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
125.96MCNYFY2025 · Dec 31, 2025Research & Development
45.78MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
95.52MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.45MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
17.10MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.54MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.2200CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.2200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
138.71MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
138.71MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-10.48MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-20.03MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-264.36MCNYFY2025 · Dec 31, 2025Free Cash Flow
-398.30MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.22BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-10.48MCNYFY2025 · Dec 31, 2025Other Non-cash Items
15.57MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-104.52MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-164.93MCNYFY2025 · Dec 31, 2025Capital Expenditures
-133.94MCNYFY2025 · Dec 31, 2025Purchase of Investments
-100.34MCNYFY2025 · Dec 31, 2025Sale of Investments
100.34MCNYFY2025 · Dec 31, 2025Other Investing Activity
11.84MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-122.10MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-500.00KCNYFY2025 · Dec 31, 2025Common Dividends Paid
-45.12MCNYFY2025 · Dec 31, 2025Other Financing Charges
-16.54MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-62.16MCNYFY2025 · Dec 31, 2025Shares Outstanding
140.98MSharesUpdated Aug 21, 2026Float Shares
118.89MSharesUpdated Aug 21, 2026% Held by Insiders
63.08%vs all stocks
% Held by Institutions
10.82%vs all stocks
Total Cash (MRQ)
1.34BCNY199.54M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.52CNYUpdated Aug 21, 2026Total Debt (MRQ)
130.70MCNY19.44M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0550xCurrent Ratio (MRQ)
2.84xBook Value per Share (MRQ)
16.58CNYUpdated Aug 21, 2026Total Assets
3.25BCNY483.82M · vs all stocks (USD)
Total Current Assets
2.18BCNYFY2025 · Dec 31, 2025Total Liabilities
891.41MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.07BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
179.22MCNYFY2025 · Dec 31, 2025Total Current Liabilities
712.19MCNYFY2025 · Dec 31, 2025Cash
979.05MCNYFY2025 · Dec 31, 2025Cash Equivalents
308.03MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.29BCNYFY2025 · Dec 31, 2025Accounts Receivable
218.23MCNYFY2025 · Dec 31, 2025Inventory
430.46MCNYFY2025 · Dec 31, 2025Accounts Payable
69.00MCNYFY2025 · Dec 31, 2025Short-term Debt
11.09MCNYFY2025 · Dec 31, 2025Other Current Liabilities
6.87MCNYFY2025 · Dec 31, 2025Long-term Debt
104.59MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
6.16MCNYFY2025 · Dec 31, 2025Common Stock (Book)
140.98MCNYFY2025 · Dec 31, 2025Retained Earnings
453.08MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.36BCNY351.26M · vs all stocks (USD)
52-Week Low
37.00CNYUpdated Aug 21, 202652-Week High
103.69CNYUpdated Aug 21, 202652-Week Change
127.16%vs all stocks
50-Day MA
72.98CNYUpdated Aug 21, 2026200-Day MA
61.18CNYUpdated Aug 21, 2026Avg 10-Day Volume
3.71MSharesUpdated Aug 21, 2026Avg 30-Day Volume
4.36MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.1700CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 17.47Revenue Growth YoY: 0.00
Financial Health
Altman Z-Score 10.02: safe zoneNotable
Altman Z-Score: 10.02
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Market cap is $2B, above the global median of $1.15BNotable
Market cap (USD): 1,996,923,731.457Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Viridian Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Healthgen Biotechnology Corp.
Tier 1ProductionApproval-Gated PipelineRule
Nuvation Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Syndax Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sk Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
GH Research plc
Tier 1ProductionApproval-Gated PipelineRule
Ocular Therapeutix Inc.
Tier 1ProductionApproval-Gated PipelineRule
Caplin Point Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule